SalaryGuide
SalariesCompaniesJobs
AboutPricingBlog
For Employers

Marketing jobs

6 marketing jobs

Servier Pharmaceuticals logo
4 weeks ago

Sr. Director/Director, Neurology Patient Marketing

Servier Pharmaceuticals

USA (Hybrid)Full time$245K/yr – $307K/yr
Servier Pharmaceuticals logo
4 weeks ago

Sr. Director, HCP Marketing (Neurology)

Servier Pharmaceuticals

USA (Hybrid)Full time$251K/yr – $307K/yr
Servier Pharmaceuticals logo
4 weeks ago

Associate Director, External Communications

Servier Pharmaceuticals

Boston, MA (Hybrid)Full time$156K/yr – $185K/yr
Servier Pharmaceuticals logo
6 weeks ago

Sr. Marketing Manager, Patient Marketing

Servier Pharmaceuticals

Boston, MA (Remote)Full time$147K/yr – $168K/yr
Servier Pharmaceuticals logo
2 months ago

Senior Manager, Pipeline and Neurology Communications

Servier Pharmaceuticals

Boston, MA (Hybrid)Full time$142K/yr – $162K/yr
Servier Pharmaceuticals logo
3 months ago

Sr. Mgr, Brand Marketing (Glioma/Solid Tumors)

Servier Pharmaceuticals

Boston, MA (Hybrid)Full time$147K/yr – $168K/yr

All marketing roles in the US

Get alerts for this search

All marketing roles in the US

Get alerts for this search

6 jobs
Servier Pharmaceuticals logo

Sr. Director/Director, Neurology Patient Marketing

Servier Pharmaceuticals

USA (Hybrid)

$245K/yr - $307K/yrIn-houseFull-timeSenior level
4 weeks ago
Servier Pharmaceuticals logo

Sr. Director, HCP Marketing (Neurology)

Servier Pharmaceuticals

USA (Hybrid)

$251K/yr - $307K/yrIn-houseFull-timeSenior level
4 weeks ago
Servier Pharmaceuticals logo

Associate Director, External Communications

Servier Pharmaceuticals

Boston, MA (Hybrid)

$156K/yr - $185K/yrIn-houseFull-timeSenior level8+ years exp.
4 weeks ago
Servier Pharmaceuticals logo

Sr. Marketing Manager, Patient Marketing

Servier Pharmaceuticals

Boston, MA (Remote)

$147K/yr - $168K/yrIn-houseFull-timeSenior level6+ years exp.
6 weeks ago
Servier Pharmaceuticals logo

Senior Manager, Pipeline and Neurology Communications

Servier Pharmaceuticals

Boston, MA (Hybrid)

$142K/yr - $162K/yrIn-houseFull-timeSenior level7+ years exp.
2 months ago
Servier Pharmaceuticals logo

Sr. Mgr, Brand Marketing (Glioma/Solid Tumors)

Servier Pharmaceuticals

Boston, MA (Hybrid)

$147K/yr - $168K/yrIn-houseFull-timeSenior level5+ years exp.
3 months ago
Servier Pharmaceuticals logo
Servier Pharmaceuticals

Sr. Director/Director, Neurology Patient Marketing

USA (Hybrid)

$245K/yr – $307K/yrSenior LevelFull time

Posted 4 weeks ago

  • Job
  • Company
  • Salaries
  • People
  • Audience
  • News
  • Links

Job Summary

Own the end-to-end patient marketing strategy for Becker, leading lifecycle campaigns, patient education initiatives, and strategic advocacy partnerships to drive patient activation and ROI.

  • Own patient marketing strategy, lifecycle campaigns, and ROI measurement
  • Lead cross-functional collaboration with Digital Marketing, Insights, and patient advocacy partners

Job Description

Responsibilities

  • Architect and spearhead the overarching patient marketing vision, ensuring strategic alignment from pre-launch through mature lifecycle management
  • Direct the end-to-end development and execution of high-impact disease state awareness and branded patient campaigns that resonate with the rare disease community
  • Formulate and refine differentiated patient value propositions that articulate unique clinical and quality-of-life benefits to Becker patients and their families
  • Champion the end-to-end patient journey, identifying critical inflection points to optimize the overall patient experience and the care continuum
  • Orchestrate sophisticated omnichannel engagement strategies in collaboration with Digital Marketing, ensuring seamless caregiver and patient experiences across all digital touchpoints
  • Cultivate and scale patient ambassador initiatives, empowering authentic community voices to drive brand connection and peer-to-peer support
  • Oversee the creation of a robust ecosystem of patient-centric educational resources designed to simplify complex clinical concepts and empower informed decision-making
  • Forge and maintain strategic alliances with key Patient Advocacy organizations to ensure enterprise alignment with the evolving needs of the community
  • Synthesize qualitative patient insights to serve as a foundational pillar for brand strategy and organizational decision-making
  • Drive community-focused educational initiatives that increase disease awareness and foster long-term trust within the advocacy landscape

Requirements

  • Bachelor's degree required; MBA preferred
  • 12+ years pharmaceutical/biotech marketing experience
  • 7+ years patient or consumer marketing
  • Demonstrated success launching specialty or rare disease products
  • Rare disease and neurology experience strongly preferred
  • Strong understanding of patient advocacy organizations and patient services
  • Demonstrated experience in developing disease awareness campaigns and patient education strategies
  • Proven agency and budget management experience
  • Strong understanding of promotional compliance
  • Demonstrate excellent verbal and written communication skills

Preferred

  • MBA preferred

Benefits

  • Servier’s benefits package includes medical, dental, vision, flexible time off (unlimited sick time and flex time), 401(k), life and disability insurance, recognition programs among other great benefits (all benefits subject to eligibility requirements).
Servier Pharmaceuticals logo

Servier Pharmaceuticals

Servier is a privately held international pharmaceutical company headquartered in France with a passion for innovation that has improved patients’ lives around the world. With $4.7 billion in annual sales Servier operates in almost 150 countries worldwide across five therapeutic categories including oncology, cardiovascular, immuno-inflammatory, neuroscience and diabetes. Servier is founded on the principle of serving and governed by an independent non-profit foundation. With this unique operating model, the company can be deliberate about putting patients ahead of profits. In fact, Servier re-invests 25 percent of revenue into research and development each year. Servier is committed to therapeutic progress to serve patient needs and strives to provide future generations with a world where quality healthcare is available and accessible to all.See our community guidelines here: https://www.servier.us/community-guidelinesTo report a suspected adverse event with a Servier product, please visit: https://www.servier.us/contact-us

Founded in 2018
Boston, Massachusetts, USA
961 employees (61 in marketing)
www.servier.us

Salaries

Posted range

$245K/yr – $307K/yr

Taken straight from the job posting.

See all Servier Pharmaceuticals salaries

Marketing Team

Marketing Team Size
58 (6% of company)
Median Career Experience
9 years
Median Tenure
2.6 years
Marketing Roles Posted (Last 30 Days)
4

People

Marketing Leadership

Juby C.
Senior Manager, Oncology Product Marketing - Hematology
At the company for 5 months

Traffic Signals

Monthly Visitors
6.9K
Traffic Source Mix
Search
30.3%
Direct
45.8%
Referral
6.8%
Social
15.5%
Paid
1.5%

Headcount Trend

Current headcount: ~963

Recent News

Servier Pharmaceuticals Welcomes Servier México Team to U.S. Office to Advance Strategic Alignment
Dec 16, 2025 • Oncodaily
Servier Pharmaceuticals at 2025 ASH Annual Meeting
Dec 9, 2025 • Oncodaily
Proud to Join the Neuro-Oncology Community at SNO2025 – Servier Pharmaceuticals
Nov 11, 2025 • Oncodaily
Servier India launches biomarker testing initiative for AML and Cholangiocarcinoma patients
Nov 11, 2025 • Express Pharma
Servier India partners with Medgenome and Strand Lifesciences advance biomarker testing for IDH-mutated AML
Nov 11, 2025 • Express Healthcare
Servier India partners with two genomic laboratories to advance specific type of cancer testing
Nov 11, 2025 • BusinessLine
Servier India rolls out affordable biomarker testing for leukaemia and bile duct cancer patients
Nov 11, 2025 • Business Today
Servier India launch affordable biomarker testing for leukaemia, bile duct cancer
Nov 11, 2025 • The New Indian Express
Servier India launches subsidised biomarker tests for rare cancers
Nov 11, 2025 • Business Standard
Servier India Partners with MedGenome & Strand Life Sciences, Expanding AML & CCA Testing
Nov 11, 2025 • eHealth Magazine
Servier's Clinical and Real-World Data at 2025 SNO Congress Showcase Leadership in IDH-Mutant Glioma
Nov 10, 2025 • WV News
Servier's Clinical and Real-World Data at 2025 SNO Congress Showcase Leadership in IDH-Mutant Glioma
Nov 10, 2025 • PR Newswire
Servier Pharmaceuticals Wins Prix Galien for Innovation in Rare Disease
Nov 7, 2025 • Oncodaily
Servier's New and Updated Data at 2025 ASH Annual Meeting Highlight Commitment to Hematology Research
Nov 6, 2025 • PR Newswire
Servier Pharmaceuticals Honored with 2025 Prix Galien USA Award
Nov 5, 2025 • Oncodaily
Servier Announces Positive Findings from Longer-Term Analysis of the Phase 3 INDIGO Trial Showing Continued Durable Treatment Effect of VORANIGO® (vorasidenib) Published in The Lancet Oncology
Nov 4, 2025 • BioSpace
Servier Announces Positive Findings from Longer-Term Analysis of the Phase 3 INDIGO Trial Showing Continued Durable Treatment Effect of VORANIGO® (vorasidenib) Published in The Lancet Oncology
Nov 3, 2025 • PR Newswire
Servier's VORANIGO® (vorasidenib) Receives Prestigious 2025 Prix Galien USA Award
Oct 31, 2025 • PR Newswire
“It Means The World”: Celebrating Global Patient Week – Servier Pharmaceuticals
Oct 11, 2025 • Oncodaily
Technology at the Heart of Servier’s Patient-First Approach
Oct 6, 2025 • AI Magazine
Technology at the Heart of Servier’s Patient-First Approach
Oct 6, 2025 • Technology Magazine
Servier Pharmaceuticals Opens Applications for a Meeting with Servier
Sep 24, 2025 • Oncodaily
EC approves Servier’s Voranigo to treat IDH-mutant glioma
Sep 23, 2025 • Pharmaceutical Technology
Servier wins EU nod for Voranigo in IDH-mutant glioma
Sep 22, 2025 • The Pharma Letter
European Commission Approves Servier's VORANIGO® (vorasidenib) as the First Targeted Therapy for Grade 2 IDH-Mutant Glioma in the EU
Sep 22, 2025 • PR Newswire
Baker McKenzie advises Servier on the acquisition of a potential treatment for Fragile X syndrome
Sep 18, 2025 • Baker McKenzie
Servier’s Voranigo backed by MHRA for astrocytoma or oligodendroglioma
Sep 16, 2025 • The Pharma Letter
Servier acquires Kaerus’ Fragile X syndrome candidate for up to $450m
Sep 9, 2025 • World Pharmaceutical Frontiers
Servier to acquire potential Fragile X syndrome treatment from Kaerus
Sep 9, 2025 • Pharmaceutical Technology
Servier to Acquire Kaerus Bioscience’s Autism Drug in Potential $450M Deal
Sep 8, 2025 • contractpharma.com
Servier supercharges neuro pipeline with $450M deal for Fragile X syndrome candidate
Sep 8, 2025 • Fierce Biotech
Servier acquires potential treatment for Fragile X syndrome, the most common genetic cause of autism spectrum disorder
Sep 8, 2025 • PR Newswire
Servier Buys Fragile X Syndrome Candidate for up to $450M
Sep 8, 2025 • Genetic Engineering and Biotechnology News
Servier acquires treatment for autism genetic cause Fragile X syndrome
Sep 8, 2025 • European Pharmaceutical Review
Servier acquires potential treatment for Fragile X syndrome
Sep 8, 2025 • Servier
Desmond Murphy Starts a New Role as U.S. Oncology Assets Liaison at Servier Pharmaceuticals
Sep 7, 2025 • Oncodaily
Novartis-Arrowhead, Servier -Ideaya partnerships refresh balance sheets: Deals Report
Sep 3, 2025 • BioCentury
Servier pays big for ex-US darovasertib rights
Sep 2, 2025 • The Pharma Letter
Servier and IDEAYA Biosciences Partner to Bring Darovasertib, a Promising Uveal Melanoma Treatment, to Patients Worldwide
Sep 2, 2025 • PR Newswire
Servier pays $200M upfront to Ideaya; Zymeworks ends work on T cell engager
Sep 2, 2025 • Endpoints News
Servier pockets ex-US rights to IDEAYA’s eye cancer drug in $530M deal
Sep 2, 2025 • FirstWord Pharma
Servier and IDEAYA Biosciences Partner to Bring Darovasertib, a Promising Uveal Melanoma Treatment, to Patients Worldwide
Sep 2, 2025 • Yahoo Finance
Prapti Patel: Servier is Hiring a Medical Director for the Late Stage-Life Cycle Management team
Aug 31, 2025 • Oncodaily
The future of patient support: Servier’s approach to care and innovation
Aug 29, 2025 • BioXconomy
Profit halves at French pharma giant Servier’s Irish operations as revenue falls 70%
Aug 19, 2025 • Business Post
Servier’s Therapy for IDH Mutant Glioma was Nominated for 2025 Prix Galien USA Award
Aug 12, 2025 • Oncodaily
Marking One Year of Progress in IDH-Mutant Glioma Treatment – Servier Pharmaceuticals
Aug 7, 2025 • Oncodaily
CDSCO gives positive recommendation to Servier to use Vorasidenib for brain cancer patients
Aug 6, 2025 • BioSpectrum India
Cholangiocarcinoma Market Analysis Report 2025-2035 | Rising Incidence, Advanced Diagnostics, and Precision Medicine Driving Novel Therapeutic Development
Aug 5, 2025 • Research and Markets
Dentons advises Servier on the sale of Biogaran
Jul 31, 2025 • Dentons
BC Partners in talks to buy Biogaran from Servier
Jul 30, 2025 • pehub.com
France: Servier and BC Partners open negotiations for the sale of Biogaran
Jul 30, 2025 • Investors in Healthcare
BC Partners to Acquire Servier’s Generic Drug Unit Biogaran
Jul 30, 2025 • Bloomberg.com
Servier Announces Positive Data from Long-Term Follow-Up Analysis of the Phase 3 AGILE Trial of TIBSOVO® (ivosidenib) in IDH1-mutated Acute Myeloid Leukemia
Jul 28, 2025 • PR Newswire
Servier Receives Positive CHMP Opinion for VORANIGO® (vorasidenib) for the Treatment of Adults and Adolescents with Grade 2 IDH-mutant Diffuse Glioma
Jul 28, 2025 • BioSpace
Servier Receives Positive CHMP Opinion for VORANIGO® (vorasidenib) for the Treatment of Adults and Adolescents with Grade 2 IDH-mutant Diffuse Glioma
Jul 25, 2025 • PR Newswire
The End Brain Cancer Initiative Partners with Servier to Spread Awareness of IDH1 and IDH2 Markers
Jul 24, 2025 • EIN Presswire
French drugmaker Servier targets India expansion with cancer therapies, R&D
Jun 26, 2025 • Moneycontrol
Servier India introduces targeted therapy in oncology for rare IDH1-mutated AML and cholangiocarcinoma
Jun 5, 2025 • BioSpectrum India
Servier India launches IDH1-targeted therapy Ivosidenib for AML and Cholangiocarcinoma
Jun 5, 2025 • Express Pharma
Servier tackles environmental challenges, transforming itself for a more sustainable future!
Jun 5, 2025 • Servier
Servier India introduces 'Ivosidenib'(Tibsovo®), in India, First-in-class Targeted Therapy in Oncology for Rare IDH1-Mutated AML and Cholangiocarcinoma
Jun 5, 2025 • Business Standard
Servier Ranked Among Top Companies Across Several Categories in 2024 PatientView Corporate Reputation of Pharma Survey
May 28, 2025 • PR Newswire
Servier Ranked Among Top Companies Across Several Categories in 2024 PatientView Corporate Reputation of Pharma Survey
May 28, 2025 • Yahoo Finance
Servier Acquires Precision Therapy for Acute Leukemias from BioNova Pharmaceuticals
May 24, 2025 • Oncodaily
Servier to acquire BioNova leukemia therapy
May 23, 2025 • The Pharma Letter
Servier joins the menin club | ApexOnco - Clinical Trials news and analysis
May 23, 2025 • Oncology Pipeline
Servier turns to China as it adds menin inhibitor to oncology pipeline
May 23, 2025 • FirstWord Pharma
Servier Presentations at ASCO 2025 Reinforce Company Leadership in IDH-Mutated Cancers
May 22, 2025 • PR Newswire
Servier reaches settlement with EU over interest on antitrust fine
May 15, 2025 • MLex
Global Cholangiocarcinoma (CCA) Therapeutics Market Set t...
May 2, 2025 • PharmiWeb
Servier severing forces OPM to make 'drastic choices' to adapt as it cuts staff, executive wages
Apr 4, 2025 • Fierce Biotech
Servier unveils new production unit in France
Mar 26, 2025 • The Pharma Letter
Servier and Black Diamond sign deal for solid tumours therapies
Mar 20, 2025 • Pharmaceutical Technology
Ropes & Gray Advises Black Diamond Therapeutics in Global Licensing Deal with Servier
Mar 19, 2025 • Ropes & Gray
Servier Nabs Solid Tumor Asset in up to $780M Deal With Black Diamond
Mar 19, 2025 • BioSpace
Servier Egypt celebrates Platinum Jubilee with expansion of state-of-the-art production line
Feb 6, 2025 • ZAWYA
Servier Adopts Veeva RIM
Feb 4, 2025 • contractpharma.com
Servier delivers strong results for 2023/24 financial year
Jan 29, 2025 • The Pharma Letter
Servier delivers strong results in 2023/2024 and outpaces its trajectory to 2030
Jan 28, 2025 • Servier
JPM25: As Servier cements oncology bona fides, US chief stresses importance of 'staying authentic'
Jan 23, 2025 • Fierce Pharma
David Lee: Staying true to our purpose at Servier Pharmaceuticals
Jan 23, 2025 • Oncodaily
Servier Plots Route Into Neurology Through BD
Jan 22, 2025 • insights.citeline.com
Inside Google Cloud's Renewed Collaboration With Servier
Jan 20, 2025 • Technology Magazine
Pharmaceutical developer Servier expands partnership with Google AI
Jan 18, 2025 • Data Center Dynamics
Servier and Google Cloud Expand Partnership on using data and AI
Jan 16, 2025 • Servier
Servier and Google Cloud Expand Partnership on using Data and AI
Jan 16, 2025 • PR Newswire
Servier Introduces Cosyrel: A Novel SPC for Hypertension and Post-MI Care
Jan 16, 2025 • Medical Dialogues
Servier appoints David K. Lee to Executive Committee
Jan 13, 2025 • Servier
Servier Announces Expansion of its Tibsovo (ivosidenib) Development Program Investigating its Safety and Efficacy in Patients Living with IDH1-Mutated Cancers in Both Hematological Malignancies and Solid Tumors
Jan 9, 2025 • PR Newswire
Servier inaugurates a bioproduction plant in France to support the growth of its R&D programs
Nov 27, 2024 • Servier
Servier to Present Data on IDH-mutant Glioma at the 2024 Society for Neuro-Oncology (SNO) Congress
Nov 12, 2024 • PR Newswire
Servier gets Health Canada nod for Voranigo to treat brain cancer
Oct 23, 2024 • World Pharmaceutical Frontiers
Therapy for treating malignancies
Aug 7, 2024 • Google Patent
Cocrystal of an idh1 inhibitor, process of preparation thereof, pharmaceutical …
Aug 1, 2024 • Google Patent
Salts, cocrystals, pharmaceutical compositions thereof, and methods of …
Jul 25, 2024 • Google Patent
Combination therapy for treating malignancies
Jun 24, 2024 • Google Patent
Servier Pharmaceuticals on LinkedIn: #boston
Jun 19, 2024 • LinkedIn
Methods of treating brain tumors using combination therapy
Jun 11, 2024 • Google Patent
Servier Initiates Critical Dialogue on AYA Cancer Survivorship at ASCO 2024
May 30, 2024 • PR Newswire

Links

www.servier.usLinkedInX (Twitter)Crunchbase

This role is listed on SalaryGuide for informational purposes. SalaryGuide is not the employer, recruitment agency, or hiring representative for this position. Hiring decisions and the application process are managed by the employer. SalaryGuide will never ask candidates to pay to apply for a job or request bank details or identification documents as part of an application.